Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1980 1
1985 1
1987 1
1997 2
2000 1
2002 1
2004 1
2005 1
2006 1
2007 1
2008 1
2009 1
2010 2
2011 2
2012 1
2013 1
2016 1
2017 1
2019 8
2020 8
2021 4
2022 5
2023 4
2024 9
2025 13

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

71 results

Results by year

Filters applied: . Clear all
Page 1
Quadrivalent influenza nanoparticle vaccines induce broad protection.
Boyoglu-Barnum S, Ellis D, Gillespie RA, Hutchinson GB, Park YJ, Moin SM, Acton OJ, Ravichandran R, Murphy M, Pettie D, Matheson N, Carter L, Creanga A, Watson MJ, Kephart S, Ataca S, Vaile JR, Ueda G, Crank MC, Stewart L, Lee KK, Guttman M, Baker D, Mascola JR, Veesler D, Graham BS, King NP, Kanekiyo M. Boyoglu-Barnum S, et al. Among authors: gillespie ra. Nature. 2021 Apr;592(7855):623-628. doi: 10.1038/s41586-021-03365-x. Epub 2021 Mar 24. Nature. 2021. PMID: 33762730 Free PMC article.
SARS-CoV-2 mRNA vaccine design enabled by prototype pathogen preparedness.
Corbett KS, Edwards DK, Leist SR, Abiona OM, Boyoglu-Barnum S, Gillespie RA, Himansu S, Schäfer A, Ziwawo CT, DiPiazza AT, Dinnon KH, Elbashir SM, Shaw CA, Woods A, Fritch EJ, Martinez DR, Bock KW, Minai M, Nagata BM, Hutchinson GB, Wu K, Henry C, Bahl K, Garcia-Dominguez D, Ma L, Renzi I, Kong WP, Schmidt SD, Wang L, Zhang Y, Phung E, Chang LA, Loomis RJ, Altaras NE, Narayanan E, Metkar M, Presnyak V, Liu C, Louder MK, Shi W, Leung K, Yang ES, West A, Gully KL, Stevens LJ, Wang N, Wrapp D, Doria-Rose NA, Stewart-Jones G, Bennett H, Alvarado GS, Nason MC, Ruckwardt TJ, McLellan JS, Denison MR, Chappell JD, Moore IN, Morabito KM, Mascola JR, Baric RS, Carfi A, Graham BS. Corbett KS, et al. Among authors: gillespie ra. Nature. 2020 Oct;586(7830):567-571. doi: 10.1038/s41586-020-2622-0. Epub 2020 Aug 5. Nature. 2020. PMID: 32756549 Free PMC article.
An mRNA Vaccine against SARS-CoV-2 - Preliminary Report.
Jackson LA, Anderson EJ, Rouphael NG, Roberts PC, Makhene M, Coler RN, McCullough MP, Chappell JD, Denison MR, Stevens LJ, Pruijssers AJ, McDermott A, Flach B, Doria-Rose NA, Corbett KS, Morabito KM, O'Dell S, Schmidt SD, Swanson PA 2nd, Padilla M, Mascola JR, Neuzil KM, Bennett H, Sun W, Peters E, Makowski M, Albert J, Cross K, Buchanan W, Pikaart-Tautges R, Ledgerwood JE, Graham BS, Beigel JH; mRNA-1273 Study Group. Jackson LA, et al. N Engl J Med. 2020 Nov 12;383(20):1920-1931. doi: 10.1056/NEJMoa2022483. Epub 2020 Jul 14. N Engl J Med. 2020. PMID: 32663912 Free PMC article. Clinical Trial.
Co-immunization with hemagglutinin stem immunogens elicits cross-group neutralizing antibodies and broad protection against influenza A viruses.
Moin SM, Boyington JC, Boyoglu-Barnum S, Gillespie RA, Cerutti G, Cheung CS, Cagigi A, Gallagher JR, Brand J, Prabhakaran M, Tsybovsky Y, Stephens T, Fisher BE, Creanga A, Ataca S, Rawi R, Corbett KS, Crank MC, Karlsson Hedestam GB, Gorman J, McDermott AB, Harris AK, Zhou T, Kwong PD, Shapiro L, Mascola JR, Graham BS, Kanekiyo M. Moin SM, et al. Among authors: gillespie ra. Immunity. 2022 Dec 13;55(12):2405-2418.e7. doi: 10.1016/j.immuni.2022.10.015. Epub 2022 Nov 9. Immunity. 2022. PMID: 36356572 Free PMC article.
An influenza hemagglutinin stem nanoparticle vaccine induces cross-group 1 neutralizing antibodies in healthy adults.
Widge AT, Hofstetter AR, Houser KV, Awan SF, Chen GL, Burgos Florez MC, Berkowitz NM, Mendoza F, Hendel CS, Holman LA, Gordon IJ, Apte P, Liang CJ, Gaudinski MR, Coates EE, Strom L, Wycuff D, Vazquez S, Stein JA, Gall JG, Adams WC, Carlton K, Gillespie RA, Creanga A, Crank MC, Andrews SF, Castro M, Serebryannyy LA, Narpala SR, Hatcher C, Lin BC, O'Connell S, Freyn AW, Rosado VC, Nachbagauer R, Palese P, Kanekiyo M, McDermott AB, Koup RA, Dropulic LK, Graham BS, Mascola JR, Ledgerwood JE; VRC 321 study team. Widge AT, et al. Among authors: gillespie ra. Sci Transl Med. 2023 Apr 19;15(692):eade4790. doi: 10.1126/scitranslmed.ade4790. Epub 2023 Apr 19. Sci Transl Med. 2023. PMID: 37075129 Free PMC article. Clinical Trial.
Pre-exposure antibody prophylaxis protects macaques from severe influenza.
Kanekiyo M, Gillespie RA, Cooper K, Canedo VG, Castanha PMS, Pegu A, Yang ES, Treaster L, Yun G, Wallace M, Kettenburg G, Williams C, Lundy J, Barrick S, O'Malley K, Midgett M, Martí MM, Chavva H, Corry J, Treat BR, Lipinski A, Batsche LO, Creanga A, Ritter I, Walker R, Olsen E, Laughlin A, Perez DR, Mascola JR, Boritz EA, Loo YM, Blair W, Esser M, Graham BS, Reed DS, Barratt-Boyes SM. Kanekiyo M, et al. Among authors: gillespie ra. Science. 2025 Jan 31;387(6733):534-541. doi: 10.1126/science.ado6481. Epub 2025 Jan 30. Science. 2025. PMID: 39883776
Phase 1 dose-escalation trial evaluating a group 2 influenza hemagglutinin stabilized stem nanoparticle vaccine.
Casazza JP, Hofstetter AR, Costner PJM, Holman LA, Hendel CS, Widge AT, Wu RL, Whalen WR, Cunningham J, Arthur A, Wang X, Ola A, Saunders J, Mendoza F, Novik L, Burgos Florez MC, Ortega-Villa AM, Apte PJ, Strom L, Wang L, Imam M, Basappa M, Naisan M, Castro M, Trost JF, Narpala SR, Vanderven HA, Yamshchikov GV, Berkowitz NM, Gordon IJ, Plummer SH, Wycuff DL, Vazquez S, Gillespie RA, Creanga A, Adams WC, Carlton K, Gall JG, McDermott AB, Serebryannyy LA, Houser KV, Koup RA, Graham BS, Ledgerwood JE, Mascola JR, Pierson TC, Andrews SF, Kanekiyo M, Dropulic LK; VRC 323 study team. Casazza JP, et al. Among authors: gillespie ra. NPJ Vaccines. 2024 Sep 17;9(1):171. doi: 10.1038/s41541-024-00959-0. NPJ Vaccines. 2024. PMID: 39289377 Free PMC article.
Early influenza virus exposure shapes the B cell response to influenza vaccination in individuals 50 years later.
Spangler A, Shimberg GD, Mantus GE, Malek R, Cominsky LY, Tsybovsky Y, Li N, Gillespie RA, Ravichandran M, Creanga A, Raab JE, Gajjala SR, Mendoza F, Houser KV, Dropulic L, McDermott AB, Kanekiyo M, Andrews SF. Spangler A, et al. Among authors: gillespie ra. Immunity. 2025 Mar 11;58(3):728-744.e9. doi: 10.1016/j.immuni.2025.02.004. Epub 2025 Feb 28. Immunity. 2025. PMID: 40023164
Antibody sequence determinants of viral antigen specificity.
Abu-Shmais AA, Vukovich MJ, Wasdin PT, Suresh YP, Marinov TM, Rush SA, Gillespie RA, Sankhala RS, Choe M, Joyce MG, Kanekiyo M, McLellan JS, Georgiev IS. Abu-Shmais AA, et al. Among authors: gillespie ra. mBio. 2024 Oct 16;15(10):e0156024. doi: 10.1128/mbio.01560-24. Epub 2024 Sep 12. mBio. 2024. PMID: 39264172 Free PMC article.
Glycan-reactive antibodies isolated from human HIV-1 vaccine trial participants show broad pathogen cross-reactivity.
Jamieson PJ, Shen X, Abu-Shmais AA, Wasdin PT, Janowska K, Edwards RJ, Scapellato G, Richardson SI, Manamela NP, Liu S, Barr M, Gillespie RA, Mimms J, Suryadevara N, Sornberger TA, Zost S, Parks R, Flaherty S, Janke AK, Howard BN, Suresh YP, Ruprecht RM, Crowe JE Jr, Carnahan RH, Bailey JR, Masaru K, Haynes BF, Moore PL, Acharya P, Montefiori DC, Kalams SA, Lu S, Georgiev IS. Jamieson PJ, et al. Among authors: gillespie ra. bioRxiv [Preprint]. 2025 Jan 20:2025.01.17.633475. doi: 10.1101/2025.01.17.633475. bioRxiv. 2025. PMID: 39896680 Free PMC article. Preprint.
71 results